Severe Hypoglycemia – Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Severe Hypoglycemia – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Severe Hypoglycemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Severe hypoglycemia: Overview
Hypoglycemia is a common side effect of diabetes therapy, resulting in a lack of adequate cerebral glucose supply, leading to a range of neurogenic and neuroglycopenic symptoms, which in turn can lead to death, if not treated on time. Intensive glycemic control significantly increases the risk of hypoglycemia in patients with diabetes mellitus. Severe hypoglycemia is a high-risk state and is followed by a high rate of cardiovascular events and deaths in persons with diabetes.
Symptoms
The symptoms of Severe Hypoglycemia include:
Structured educational and psycho-behavioural programs (e.g. BG awareness training) may help improve detection of hypoglycemia and reduce the frequency of severe hypoglycemia.
Treatment
The goals of treatment for hypoglycemia are to detect and treat a low BG level promptly by using an intervention that provides the fastest rise in BG to a safe level, to eliminate the risk of injury and to relieve symptoms quickly. It is also important to avoid overtreatment since this can result in rebound hyperglycemia and weight gain. Glucose gel is quite slow and must be swallowed to have a significant effect. People taking an alpha glucosidase inhibitor (acarbose) must use glucose (dextrose) tablets or, if unavailable, milk or honey to treat hypoglycemia. Islet cell transplantation, which has been shown to reduce hypoglycemia and restore glucose counter-regulation, should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia.
Severe Hypoglycemia Emerging Drugs Chapters
This segment of the Severe Hypoglycemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Severe Hypoglycemia Emerging Drugs
Further product details are provided in the report……..
Severe Hypoglycemia: Therapeutic Assessment
This segment of the report provides insights about the different Severe Hypoglycemia drugs segregated based on following parameters that define the scope of the report, such as:
Severe Hypoglycemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Severe Hypoglycemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Hypoglycemia drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Severe Hypoglycemia – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Severe Hypoglycemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Severe hypoglycemia: Overview
Hypoglycemia is a common side effect of diabetes therapy, resulting in a lack of adequate cerebral glucose supply, leading to a range of neurogenic and neuroglycopenic symptoms, which in turn can lead to death, if not treated on time. Intensive glycemic control significantly increases the risk of hypoglycemia in patients with diabetes mellitus. Severe hypoglycemia is a high-risk state and is followed by a high rate of cardiovascular events and deaths in persons with diabetes.
Symptoms
The symptoms of Severe Hypoglycemia include:
- Neurogenic (autonomic)- Trembling Palpitations Sweating Anxiety Hunger Nausea Tingling
- Neuroglycopenic- Difficulty concentrating Confusion, weakness, drowsiness, vision changes Difficulty speaking, headache, dizziness
Structured educational and psycho-behavioural programs (e.g. BG awareness training) may help improve detection of hypoglycemia and reduce the frequency of severe hypoglycemia.
Treatment
The goals of treatment for hypoglycemia are to detect and treat a low BG level promptly by using an intervention that provides the fastest rise in BG to a safe level, to eliminate the risk of injury and to relieve symptoms quickly. It is also important to avoid overtreatment since this can result in rebound hyperglycemia and weight gain. Glucose gel is quite slow and must be swallowed to have a significant effect. People taking an alpha glucosidase inhibitor (acarbose) must use glucose (dextrose) tablets or, if unavailable, milk or honey to treat hypoglycemia. Islet cell transplantation, which has been shown to reduce hypoglycemia and restore glucose counter-regulation, should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia.
Severe Hypoglycemia Emerging Drugs Chapters
This segment of the Severe Hypoglycemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Severe Hypoglycemia Emerging Drugs
- NN9513: Novo Nordisk
- Recombinant Human glucagon: Adocia
Further product details are provided in the report……..
Severe Hypoglycemia: Therapeutic Assessment
This segment of the report provides insights about the different Severe Hypoglycemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Severe Hypoglycemia There are approx. 30+ key companies which are developing the therapies for Severe Hypoglycemia. Majority of the drugs are in the early phases of trial.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Severe Hypoglycemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Severe Hypoglycemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Hypoglycemia drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Severe Hypoglycemia R&D. The therapies under development are focused on novel approaches to treat/improve Severe Hypoglycemia
- Severe Hypoglycemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Severe Hypoglycemia drugs?
- How many Severe Hypoglycemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Severe Hypoglycemia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Severe Hypoglycemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Severe Hypoglycemia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Adocia
- Novo Nordisk
- Zucara Therapeutics
- Recombinant human glucagon
- NN9513
- Somatostatin type 2 receptor antagonists
Introduction
Executive Summary
Severe Hypoglycemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Severe Hypoglycemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Severe Hypoglycemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Severe Hypoglycemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
RZ358: XOMA
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NN9513: Novo Nordisk
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Somatostatin type 2 receptor antagonist: Zucara Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Severe Hypoglycemia Key Companies
Severe Hypoglycemia Key Products
Severe Hypoglycemia - Unmet Needs
Severe Hypoglycemia - Market Drivers and Barriers
Severe Hypoglycemia - Future Perspectives and Conclusion
Severe Hypoglycemia Analyst Views
Severe Hypoglycemia Key Companies
Appendix
Executive Summary
Severe Hypoglycemia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Severe Hypoglycemia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Severe Hypoglycemia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Severe Hypoglycemia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
RZ358: XOMA
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
NN9513: Novo Nordisk
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Somatostatin type 2 receptor antagonist: Zucara Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Severe Hypoglycemia Key Companies
Severe Hypoglycemia Key Products
Severe Hypoglycemia - Unmet Needs
Severe Hypoglycemia - Market Drivers and Barriers
Severe Hypoglycemia - Future Perspectives and Conclusion
Severe Hypoglycemia Analyst Views
Severe Hypoglycemia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Severe Hypoglycemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Severe Hypoglycemia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Severe Hypoglycemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Severe Hypoglycemia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
